Elvina Almuradova/LinkedIn
Mar 11, 2025, 07:33
Elvina Almuradova: 177 Lu-edotreotide vs everolimus in GEP-NETs
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a post on LinkedIn:
“The Phase 3 COMPETE trial shows 177Lu-edotreotide significantly improves PFS vs everolimus in GEP-NETs.
- 23.9 vs 14.1 months; HR 0.67
- TEAEs: 82.5% vs 97%
A major step forward!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 18, 2025, 20:22
Apr 18, 2025, 20:12
Apr 18, 2025, 20:03
Apr 18, 2025, 19:54
Apr 18, 2025, 19:49
Apr 18, 2025, 19:44
Apr 18, 2025, 19:26